Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
[引用][C] Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior …
JR JOHNSON, M COHEN, LIS HSIEH… - Clinical cancer …, 2005 - pascal-francis.inist.fr
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic
non-small cell lung cancer after failure of at least one prior chemotherapy regimen CNRS Inist …
non-small cell lung cancer after failure of at least one prior chemotherapy regimen CNRS Inist …
Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: To describe the Food and Drug
Administration (FDA) review and approval of erlotinib (Tarceva, OSI Pharmaceuticals …
Administration (FDA) review and approval of erlotinib (Tarceva, OSI Pharmaceuticals …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara… - … Cancer Research: an …, 2005 - europepmc.org
Purpose To describe the Food and Drug Administration (FDA) review and approval of
erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
[PDF][PDF] Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non^ Small Cell Lung Cancer after Failure of at Least One Prior …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clin Cancer Res, 2005 - Citeseer
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara… - … : an official journal …, 2005 - pubmed.ncbi.nlm.nih.gov
Purpose To describe the Food and Drug Administration (FDA) review and approval of
erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
[PDF][PDF] Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non^ Small Cell Lung Cancer after Failure of at Least One Prior …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clin Cancer …, 2005 - researchgate.net
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …